Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Harvey Che
Observed name:
Che, Harvey
Institution:
Institute of Cancer Research
Observed institutions:
Institute of Cancer Research,
Institute of Cancer Research
ORCID:
0000-0003-1011-4653
Observed ORCID:
0000-0003-1011-4653
OpenAlex ID:
A5041199253
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
·
Clinical Cancer Research
·
38
PDF
Environment-Dependent Modes of Adaptive Evolution in Neuroblastoma: Plasticity as a Selectable Trait
2023
·
Cecilia Roux
, Sian Hamer
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
7
PDF
Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway
2022
·
Sarah A. Bird
, Amy Barber
, et al.
·
Blood
·
6
Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models
2020
·
Amy Barber
, John R Jones
, et al.
·
Blood
·
2
IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
2026
·
Sarah A. Bird
, Marco P. Licciardello
, et al.
·
Blood Neoplasia
·
1
P-179 Altered lipid metabolism in IMiD/CELMoD resistant multiple myeloma confers novel and targetable vulnerabilities
2023
·
Sarah Bird
, Yitao Xu
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
AP-1 Primes Transcriptional Noise-Led Cancer Treatment Adaptation Through KDM5 Chromatin Rewiring
2026
·
Allo Anido, Alejandro
, Roux, Cecilia
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
ID #555 Small molecule drug screening, chemoinformatics and integrative transcriptomics identify targetable MYC-dependent therapeutic vulnerabilities in high-risk medulloblastoma
2026
·
Louisa Taylor
, Beth Poole
, et al.
·
Neuro-Oncology Pediatrics
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
AP-1 Primes Transcriptional Noise-Led Cancer Treatment Adaptation Through KDM5 Chromatin Rewiring
2025
·
Alejandro Allo Anido
, Cecilia Roux
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Mdb-66. High-throughput Small Molecule Drug Screening, Transcriptomics and Integrative Ai Identify Targetable Myc-dependent Therapeutic Vulnerabilities in High-risk Medulloblastoma
2024
·
Gemma Llargués-Sistac
, Louisa Taylor
, et al.
·
Neuro-Oncology
PDF
Abstract 3879: SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models
2023
·
Sarah Anne Bird
, Marco Licciardello
, et al.
·
Cancer Research
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Data from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Show more works
View as search
Works count:
44
Citation count:
55
H-index:
3
I10-index:
1
Year
Topic
Type